Shylicine is under clinical development by Hunazine Biotech and currently in Phase II for Diarrhea. According to GlobalData, Phase II drugs for Diarrhea have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Shylicine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Shylicine overview
Shylicine is under development for the treatment of acute watery diarrhea in cholera. It is a non-toxic cocktail consists of retinol palmitate, zinc sulfate and alisitol. It is administered through oral route and formulated as suspension. It is a unique fixed-dose combination.
It was also under development for the treatment of microvillus inclusion disease.
Hunazine Biotech overview
Hunazine Biotech is a biotechnology company focused on the development of drugs used to treat cholera disease. The company is headquartered in Cartagena, Murcia, Spain.
For a complete picture of Shylicine’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
